Related Experiment Video

Updated: Aug 23, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Various new pathogens in pneumonia]

C Regamey1

  • 1Clinique de médecine, Hôpital Cantonal, Fribourg.

Schweizerische Medizinische Wochenschrift
|November 11, 1995
PubMed

Insights

Newly identified pathogens like drug-resistant Mycobacterium tuberculosis and Hantavirus cause severe respiratory infections. Early detection and new treatment strategies are crucial for managing these emerging infectious agents.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pulmonology

Context:

  • Emerging infectious agents are increasingly implicated in lower respiratory tract infections.
  • Traditional pathogens are evolving resistance, necessitating updated diagnostic and therapeutic approaches.
  • Novel viruses and bacteria pose significant public health challenges globally.

Purpose:

  • To review and highlight newly recognized microbial agents responsible for lower respiratory tract infections.
  • To discuss the diagnostic challenges and therapeutic implications associated with these emerging pathogens.
  • To underscore the importance of surveillance and strategic management of respiratory infections.

Summary:

  • Newly identified agents include drug-resistant Mycobacterium tuberculosis, Gram-positive cocci (Streptococcus agalactiae, Enterococci), Gram-negative rods (Acinetobacter, Aeromonas hydrophila, Eikenella corrodens), intracellular organisms, and viruses.
  • Specific focus is given to penicillin G-resistant Pneumococci, Chlamydia pneumoniae, Streptococcus pyogenes (associated with severe invasive infections), and pulmonary Hantavirus syndrome.
  • The pulmonary Hantavirus syndrome, particularly in North America, presents a high mortality rate, emphasizing the need for awareness and rapid diagnosis.

Impact:

  • Highlights the evolving landscape of respiratory pathogens, including antibiotic-resistant strains and novel viruses.
  • Stresses the need for enhanced diagnostic capabilities and the development of new therapeutic strategies.
  • Informs public health initiatives and clinical practice regarding the management of severe and invasive respiratory infections.

More Related Videos

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...